Codon-Optimized mRNA for Primary Ciliary Dyskinesia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for primary ciliary dyskinesia (PCD) lack effective methods for delivering therapeutic agents to cilia, particularly due to challenges in gene therapy delivery to the lungs, which are essential for addressing the underlying ciliary defects.
Innovation Solution
The use of codon-optimized mRNA encoding DNAI1 protein encapsulated in liposomes, specifically formulated with cationic, non-cationic, and PEG-modified lipids, for pulmonary delivery, enabling targeted expression of DNAI1 protein throughout the length of cilia, thereby addressing the ciliary defects in PCD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene therapy methods are used to deliver therapeutic agents to the lungs and cilia, then treatment of PCD is attempted, but delivery efficiency and targeted expression in cilia remain insufficient
Solution Approach 1:
Lipid nanoparticles are used as intermediary carriers to deliver mRNA to ciliated cells in the lungs. The LNP formulation includes ionizable lipids, PEG-lipids, and cholesterol, which facilitate cellular uptake and targeted delivery to cilia, overcoming the limitations of conventional gene therapy methods
Solution Approach 2:
The patent employs codon-optimized mRNA sequences to enhance protein expression efficiency. By optimizing the codon usage of the DNAI1 gene, the invention achieves higher levels of functional protein expression in ciliated cells, improving delivery reliability without increasing system complexity
2Quantity of substance
If mRNA encoding DNAI1 is delivered to target tissues, then DNAI1 protein expression increases, but achieving sufficient expression throughout the length of cilia remains challenging
Solution Approach 1:
The invention delivers mRNA that is translated into DNAI1 protein, which then localizes to multiple segments along the ciliary structure. The protein expression is distributed throughout the length of cilia rather than concentrated at a single location, ensuring comprehensive coverage of the ciliary apparatus
Solution Approach 2:
The lipid nanoparticle carrier system facilitates the delivery of mRNA deep into ciliated epithelial cells, enabling the mRNA to reach the cellular compartments where cilia are formed and maintained. This intermediary delivery mechanism ensures sufficient protein expression throughout the entire ciliary length
3Productivity
If aggressive measures are taken to enhance mucus clearance and treat infections, then respiratory symptoms are managed, but the underlying ciliary defect remains unaddressed
Solution Approach 1:
The invention delivers functional DNAI1 gene copies before the ciliary defect causes severe damage. By establishing proper ciliary function through gene therapy, the treatment prevents the development of secondary complications such as chronic infections and bronchiectasis, rather than merely managing symptoms after they occur
Solution Approach 2:
The mRNA therapy enables ciliated cells to produce functional DNAI1 protein themselves, restoring the cells' ability to maintain proper ciliary structure and function. This self-service approach allows the body's own cells to correct the underlying defect without requiring continuous external intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in increased DNAI1 protein expression and activity, reducing the severity or frequency of PCD symptoms, and demonstrates improved efficacy in delivering therapeutic mRNA to target tissues, including the lungs, with potential for reduced dosing and extended treatment intervals.
Implementation Method 1
the liposome comprises one or more cationic lipids, one or more non-cationic lipids and one or more PEG-modified lipids
Implementation Method 2
administering to a subject in need of treatment an mRNA encoding human axonemal dynein intermediate chain 1 (DNAI1)
Implementation Method 3
expressed in target tissue cells and localized to and throughout the cilia, resulting in DNAI1 protein expression detectable throughout the length of cilia
Data Source
AI summary
The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal intermediate chain 1 (DNAI1) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAI1 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.